CRYSTALLINE FORMS OF N-[3-FLUORO-4-({6-(METHYLOXY)-7-[(3-MORPHOLIN-4-YLPROPYL)OXY]-QUINOLIN-4-YL}OXY)PHENYL]-N-(4-FLUOROPHENYL)CYCLOPROPANE-1, 1-DICARBOXAMIDE
This invention relates to three crystalline forms of N-[3-fluoro-4-((6-(methyloxy)- 7-[(3-morpholin-4-ylpropyl)oxy]quinolin-4-yl oxy)phenyl]-N-(4- fluorophenyl)cyclopropane-l.l-dicarboxamidc. Compound (I), designated as Form A, Form B, and Form C. The invention provides methods for treatment of cancer by exploiting the modulation of protein kinase activity. The invention also provides pharmaceutical compositions containing a crystalline form of Compound (I) and a pharmaceutically acceptable excipient.Cette invention concerne trois formes cristallines du N-[3-fluoro-4- ({6-(méthyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinoléin-4-yl}oxy)- phényl]-N-(4-fluorophényl)cyclopropane-l,l-dicarboxamide, (Composé (I)), désignées par la forme A, la forme B et la forme C. Linvention a pour objet des méthodes de traitement du cancer dans lesquelles on exploite la modulation de lactivité protéine kinase. Linvention concerne également des compositions pharmaceutiques contenant une forme cristalline du composé (I) et un excipient pharmaceutiquement acceptable.
